Bio-Techne
TECH
$72.32
+0.06%
Bio-Techne Corp. is a life sciences manufacturer that supplies consumables and instruments to the pharma, biotech, academic, and diagnostic markets, operating through two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The company is a niche leader in protein analysis reagents and spatial biology, with a global footprint and a reputation for high-quality, proprietary products. The current investor narrative is dominated by Merck KGaA's $73-per-share cash acquisition offer announced in June 2026, which has sent the stock surging and sparked debate about the deal's likelihood, regulatory hurdles, and the potential for competing bids, while also raising questions about the company's standalone growth prospects in a challenging life sciences funding environment.…
TECH
Bio-Techne
$72.32
Related headlines
Investment Opinion: Should I buy TECH Today?
Rating & Thesis: We rate Bio-Techne as a Hold, reflecting the acquisition offer that provides a floor but limited upside. The consensus analyst rating is Hold with an average target of $70.73, implying a slight downside of 2.2% from the current price. The thesis is that the stock is fairly valued near the acquisition price, and the outcome depends on the deal's completion.
Sign up to view all
TECH 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The stock is primarily driven by the acquisition outcome, which is uncertain. The fundamental business is facing revenue headwinds, but the acquisition premium provides support. If the deal closes, the stock is likely to trade near $73, offering minimal upside. If it fails, the stock could drop significantly. The key factor is the probability of deal completion, which we estimate at 85% (bull+base cases). We would upgrade to bullish if a competing bid emerges or if revenue growth resumes, and downgrade to bearish if the deal is blocked and revenue decline accelerates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bio-Techne's 12-month outlook, with a consensus price target around $70.73 and implied upside of -2.2% versus the current price.
Average Target
$70.73
0 analysts
Implied Upside
-2.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$50 - $73
Analyst target range
Analyst coverage is moderate, with 11 analysts covering the stock, and the consensus recommendation is 'Hold' with a mean rating of 2.86 (where 1 is Strong Buy and 5 is Sell). The average price target is $70.73, which is 2.2% below the current price of $72.32, implying a slight downside, indicating that analysts see limited upside at current levels. The distribution of ratings is not provided, but the 'Hold' consensus suggests a neutral stance, with recent downgrades from several firms (e.g., RBC Capital, Benchmark, TD Cowen, Citigroup, William Blair, Stephens & Co.) in June 2026, likely in response to the acquisition offer and the stock's surge.
Bulls vs Bears: TECH Investment Factors
The bull case for Bio-Techne is anchored by the Merck KGaA acquisition offer, which provides a clear valuation floor and validates the company's strategic assets. The company's high gross margins, low debt, and sequential revenue improvement support its standalone value. However, the bear case highlights the stock's limited upside from current levels, the revenue decline, and the elevated trailing PE, which could lead to downside if the deal fails. Currently, the bull case has stronger evidence given the acquisition premium and the stock's proximity to the offer price, but the key tension is the outcome of the acquisition: if it closes, the stock is likely to trade near $73; if it fails, the stock could revert to pre-offer levels around $56, representing a ~23% downside. The single most important factor is the probability of deal completion, which will determine whether the stock is a low-risk arbitrage or a high-risk standalone investment.
Bullish
- Premium acquisition offer at $73/share: Merck KGaA's cash offer of $73 per share, announced June 25, 2026, represents a ~30% premium over the pre-announcement price of ~$56. This validates the company's strategic value and provides a clear floor for the stock, as the market now prices in a high probability of deal completion.
- Strong gross margin of 65.8%: Bio-Techne's gross margin stands at 65.8%, reflecting its proprietary, high-value consumables portfolio. This is a key competitive advantage in the life sciences tools industry, supporting pricing power and profitability even during revenue softness.
- Low debt-to-equity of 0.14: With a debt-to-equity ratio of just 0.14, the company has a conservative balance sheet, providing financial flexibility and reducing bankruptcy risk. This is particularly attractive in a high-interest-rate environment and supports the acquisition financing.
- PEG ratio of 0.41 suggests undervaluation: The PEG ratio of 0.41, based on forward earnings growth, indicates the stock is trading below its growth-adjusted fair value. This suggests that if the acquisition fails, the standalone business may still offer upside potential relative to its growth prospects.
Bearish
- Revenue declined 1.5% YoY in Q3 FY2026: Q3 FY2026 revenue of $311.4M was down 1.5% year-over-year, breaking a streak of modest growth. This reflects ongoing softness in life sciences research funding, which could persist and undermine standalone growth if the acquisition fails.
- Stock trades near 52-week high with limited upside: At $72.32, the stock is just 0.4% below its 52-week high of $72.62 and 67.5% above its 52-week low. The market has already priced in the acquisition premium, leaving little room for further gains unless a higher bid emerges or the deal closes at a premium.
- Analyst consensus is Hold with downside to target: The average analyst price target is $70.73, which is 2.2% below the current price. With a mean recommendation of 2.86 (Hold), analysts see limited upside, and several firms downgraded the stock in June 2026, reflecting skepticism about the deal's completion.
- High trailing PE of 60.4x: The trailing PE ratio of 60.4x is elevated, indicating that the market is paying a premium for the stock's earnings. If the acquisition fails and growth remains sluggish, the multiple could compress, leading to significant downside.
TECH Technical Analysis
Bio-Techne's stock has been in a strong uptrend over the past year, with a 1-year price change of +33.93%, significantly outperforming the S&P 500's +20.48% gain. The current price of $72.32 sits just 0.4% below the 52-week high of $72.62, and 67.5% above the 52-week low of $43.20, indicating the stock is trading near the top of its range, reflecting strong momentum and investor optimism, though it also suggests limited upside without a breakout. The stock's beta of 1.277 indicates it is about 28% more volatile than the broader market, which is important for risk management.
Beta
1.28
1.28x market volatility
Max Drawdown
-39.3%
Largest decline past year
52-Week Range
$43-$73
Price range past year
Annual Return
+33.9%
Cumulative gain past year
| Period | TECH Return | S&P 500 |
|---|---|---|
| 1m | +0.8% | +3.6% |
| 3m | +50.0% | +2.7% |
| 6m | +25.7% | +11.4% |
| 1y | +33.9% | +18.7% |
| ytd | +21.2% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TECH Fundamental Analysis
Revenue in the most recent quarter (Q3 FY2026, ended March 31, 2026) was $311.4 million, a slight decline of 1.51% year-over-year, breaking a streak of modest growth. The multi-quarter trend shows revenue fluctuating: Q1 FY2026 was $286.6 million, Q2 FY2026 was $295.9 million, and Q3 FY2026 was $311.4 million, indicating sequential acceleration but a year-over-year dip. The company's revenue is driven by consumables (about 82.6% of total revenue), with instruments and royalties making up the remainder, and the slight decline suggests softness in research funding, though the sequential growth is encouraging.
Quarterly Revenue
$311415000.0B
2026-03
Revenue YoY Growth
-1.5%
YoY Comparison
Gross Margin
66.9%
Latest Quarter
Free Cash Flow
$269598000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TECH Overvalued?
Given that Bio-Techne is profitable (net income of $51.1 million in Q3 FY2026), the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 60.38x, while the forward PE is 31.21x, implying the market expects significant earnings growth, with the forward multiple about 48% lower than trailing, reflecting anticipated margin expansion and cost controls. The PEG ratio of 0.41 suggests the stock is undervalued relative to its expected growth rate, but this is based on analyst estimates that may be optimistic.
PE
60.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 31x~105x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
32.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Bio-Techne's financial health is generally sound, with a low debt-to-equity ratio of 0.14 and a current ratio of 4.55, indicating strong liquidity. However, the company's revenue declined 1.5% YoY in Q3 FY2026, reflecting softness in research funding, which could persist and pressure margins. The net margin of 15.0% and operating margin of 20.7% are respectable, but the trailing PE of 60.4x implies high expectations for future growth; if revenue continues to decline, earnings could miss estimates, leading to multiple compression. Additionally, the company's free cash flow of $269.6M TTM is positive, but the payout ratio of 27.4% suggests a modest dividend, which is not a major support for the stock.